Sanofi Operating Expenses 2010-2024 | SNY
Sanofi annual/quarterly operating expenses history and growth rate from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Sanofi operating expenses for the quarter ending September 30, 2024 were $11.363B, a 10.13% increase year-over-year.
- Sanofi operating expenses for the twelve months ending September 30, 2024 were $44.489B, a 14.96% increase year-over-year.
- Sanofi annual operating expenses for 2023 were $40.673B, a 9.63% increase from 2022.
- Sanofi annual operating expenses for 2022 were $37.101B, a 1.64% increase from 2021.
- Sanofi annual operating expenses for 2021 were $36.502B, a 38.8% increase from 2020.
Sanofi Annual Operating Expenses
(Millions of US $) |
| 2023 |
$40,673 |
| 2022 |
$37,101 |
| 2021 |
$36,502 |
| 2020 |
$26,298 |
| 2019 |
$34,877 |
| 2018 |
$35,902 |
| 2017 |
$33,851 |
| 2016 |
$30,815 |
| 2015 |
$31,672 |
| 2014 |
$36,807 |
| 2013 |
$36,033 |
| 2012 |
$37,697 |
| 2011 |
$38,384 |
| 2010 |
$32,044 |
| 2009 |
$31,980 |
Sanofi Quarterly Operating Expenses
(Millions of US $) |
| 2024-09-30 |
$11,363 |
| 2024-06-30 |
$10,826 |
| 2024-03-31 |
$10,538 |
| 2023-12-31 |
$11,762 |
| 2023-09-30 |
$10,318 |
| 2023-06-30 |
$9,609 |
| 2023-03-31 |
$8,984 |
| 2022-12-31 |
$9,789 |
| 2022-09-30 |
$8,924 |
| 2022-06-30 |
$9,798 |
| 2022-03-31 |
$8,590 |
| 2021-09-30 |
$9,190 |
| 2021-06-30 |
|
| 2021-03-31 |
$8,186 |
| 2020-09-30 |
$8,621 |
| 2020-03-31 |
$7,940 |
| 2019-09-30 |
$8,516 |
| 2019-03-31 |
$8,358 |
| 2018-03-31 |
$8,440 |
| 2017-12-31 |
$9,384 |
| 2017-09-30 |
$8,606 |
| 2017-06-30 |
$8,232 |
| 2017-03-31 |
$7,630 |
| 2016-12-31 |
$8,062 |
| 2016-09-30 |
$7,651 |
| 2016-06-30 |
$7,661 |
| 2016-03-31 |
$7,441 |
| 2015-09-30 |
$8,462 |
| 2015-06-30 |
$8,335 |
| 2014-06-30 |
$9,198 |
| 2013-06-30 |
$9,015 |
| 2012-06-30 |
$9,533 |
| 2012-03-31 |
$8,666 |
| 2011-12-31 |
$9,654 |
| 2011-09-30 |
$9,903 |
| 2011-06-30 |
$10,465 |
| 2011-03-31 |
$8,363 |
| 2010-12-31 |
$8,715 |
| 2010-09-30 |
$7,834 |
| 2010-06-30 |
$7,708 |
| 2010-03-31 |
$7,787 |
| 2009-12-31 |
$9,040 |
| 2009-09-30 |
$8,048 |
| 2009-06-30 |
$7,674 |
| 2009-03-31 |
$7,218 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
